Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic.

Smith KJ, Raymund M, Nowalk MP, Roberts MS, Zimmerman RK.

Am J Manag Care. 2010 Mar;16(3):200-6.

2.

Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.

Middleton DB, Lin CJ, Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS, Fox DE.

Infect Control Hosp Epidemiol. 2008 May;29(5):385-94. doi: 10.1086/587155.

PMID:
18521990
3.

Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.

Lin CJ, Zimmerman RK, Smith KJ.

Am J Manag Care. 2013 Jan 1;19(1):e30-7.

4.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
5.

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.

Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK.

Vaccine. 2010 Nov 10;28(48):7620-5. doi: 10.1016/j.vaccine.2010.09.053. Epub 2010 Sep 29.

6.

Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.

Rubin JL, McGarry LJ, Klugman KP, Strutton DR, Gilmore KE, Weinstein MC.

BMC Infect Dis. 2010 Jan 21;10:14. doi: 10.1186/1471-2334-10-14.

7.

The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.

Caldwell R, Roberts CS, An Z, Chen CI, Wang B.

BMC Infect Dis. 2015 Jul 24;15:284. doi: 10.1186/s12879-015-1021-x.

8.

Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.

Smith KJ, Zimmerman RK, Nowalk MP, Lin CJ.

J Am Geriatr Soc. 2017 Apr;65(4):763-768. doi: 10.1111/jgs.14588. Epub 2016 Dec 26.

9.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

PMID:
25919163
10.

Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.

You JH, Wong WC, Ip M, Lee NL, Ho SC.

J Epidemiol Community Health. 2009 Nov;63(11):906-11. doi: 10.1136/jech.2008.081885. Epub 2009 Jul 15.

PMID:
19608558
11.

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.

Neto JT, de Araujo GT, Gagliardi A, Pinho A, Durand L, Fonseca M.

Hum Vaccin. 2011 Oct;7(10):1037-47. doi: 10.4161/hv.7.10.15987. Epub 2011 Oct 1.

12.

Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis.

Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ.

Value Health. 2013 Mar-Apr;16(2):311-7. doi: 10.1016/j.jval.2012.11.009.

13.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
14.
15.

Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.

Wateska AR, Nowalk MP, Zimmerman RK, Smith KJ, Lin CJ.

BMC Infect Dis. 2018 Jan 25;18(1):52. doi: 10.1186/s12879-018-2967-2.

16.

Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil.

de Soárez PC, Sartori AM, Freitas AC, Nishikawa ÁM, Novaes HM.

PLoS One. 2015 Jun 26;10(6):e0130217. doi: 10.1371/journal.pone.0130217. eCollection 2015.

17.

Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013.

McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J.

J Prim Prev. 2015 Aug;36(4):259-73. doi: 10.1007/s10935-015-0394-3.

18.

Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers.

Gilchrist SA, Nanni A, Levine O.

Am J Public Health. 2012 Apr;102(4):596-605. doi: 10.2105/AJPH.2011.300512. Epub 2012 Feb 16. Review.

19.

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

Cho BH, Stoecker C, Link-Gelles R, Moore MR.

Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.

PMID:
24148572
20.

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

Asensi F, De Jose M, Lorente M, Moraga F, Ciuryla V, Arikian S, Casciano R, Vento M.

Value Health. 2004 Jan-Feb;7(1):36-51.

Supplemental Content

Support Center